Overall, this data suggests that additional research is needed across breast cancer subtypes to better refine treatment selection, including in patients with HR + /HER2- disease, as demonstrated by the patient with HR+/HER2− advanced breast cancer in our study with a duration of response greater than 245 days on pembrolizumab combination therapy. Here, ERBB2 is linked to breast carcinoma.